“…Despite the hypothetical value of a model close to the natural context with expression of antigens on RBCs, most genetic manipulation related to transfusion over the last 30 years has been carried out on more or less heterologous systems and has yielded data that has proven relevant in transfusion practices. Many studies have used human hematopoietic cell lines such as the K562 cell line derived from an erythroleukemia, the HEL myeloid leukemia cell line, KU812E derived from Chronic Myeloid Leukemia, or MEG-01 cells derived from megacaryoblastic leukemia [5][6][7][8][9][10][11]. Indeed while it would in theory provide a favorable molecular context for expression of the studied antigen [8,12], the use of human cells close to the erythroid lineage can be difficult due to native expression of the studied proteins by the cell line [13], and genetic manipulation of hematopoietic cell lines is often labor intensive when plasmid transfection techniques are used.…”